EA201500836A1 - Ингибиторы хеликазы-примазы для применения в способе лечения болезни альцгеймера - Google Patents

Ингибиторы хеликазы-примазы для применения в способе лечения болезни альцгеймера

Info

Publication number
EA201500836A1
EA201500836A1 EA201500836A EA201500836A EA201500836A1 EA 201500836 A1 EA201500836 A1 EA 201500836A1 EA 201500836 A EA201500836 A EA 201500836A EA 201500836 A EA201500836 A EA 201500836A EA 201500836 A1 EA201500836 A1 EA 201500836A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
inhibitors
helicase
alzheimer
primases
Prior art date
Application number
EA201500836A
Other languages
English (en)
Inventor
Рут Итцхаки
Original Assignee
Аикурис Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аикурис Гмбх Унд Ко. Кг filed Critical Аикурис Гмбх Унд Ко. Кг
Publication of EA201500836A1 publication Critical patent/EA201500836A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к применению ингибиторов хеликазы-примазы в способе лечения болезни Альцгеймера (AD). В частности, настоящее изобретение относится к применению ингибиторов хеликазы-примазы в способе лечения AD у индивидуума, который инфицирован HSV-1 и страдает AD или который инфицирован HSV-1 и у которого предполагается наличие AD. Предложенные противовирусные ингибиторы хеликазы-примазы воздействуют на накопление имеющих решающее значение для AD белков амилоида бета и аномально фосфорилированного белка тау, что происходит при инфицировании HSV-1.
EA201500836A 2013-02-12 2014-02-12 Ингибиторы хеликазы-примазы для применения в способе лечения болезни альцгеймера EA201500836A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13154982 2013-02-12
PCT/EP2014/052743 WO2014124978A2 (en) 2013-02-12 2014-02-12 Helicase-primase inhibitors for use in a method of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
EA201500836A1 true EA201500836A1 (ru) 2016-02-29

Family

ID=47709982

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500836A EA201500836A1 (ru) 2013-02-12 2014-02-12 Ингибиторы хеликазы-примазы для применения в способе лечения болезни альцгеймера

Country Status (16)

Country Link
US (1) US20150374676A1 (ru)
EP (1) EP2956134A2 (ru)
JP (1) JP2016507546A (ru)
KR (1) KR20150119089A (ru)
CN (1) CN105101963A (ru)
AU (1) AU2014217962A1 (ru)
BR (1) BR112015019220A2 (ru)
CA (1) CA2898798A1 (ru)
CL (1) CL2015002241A1 (ru)
EA (1) EA201500836A1 (ru)
IL (1) IL240459A0 (ru)
MX (1) MX2015010339A (ru)
PH (1) PH12015501762A1 (ru)
SG (1) SG11201506153TA (ru)
WO (1) WO2014124978A2 (ru)
ZA (1) ZA201505243B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
CN110062755B (zh) * 2016-11-28 2023-08-29 艾库里斯有限及两合公司 普瑞利韦的游离碱的马来酸盐、其药物制剂、其制造方法及其用于治疗疱疹病毒的用途
WO2022108381A1 (ko) 2020-11-19 2022-05-27 주식회사 오에이티씨 디다노신을 포함하는 신경염증성 질환 예방 또는 치료용 조성물
WO2024047508A1 (en) * 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8299059B2 (en) * 2009-10-30 2012-10-30 Eli Lilly And Company Crystalline compound and a process for its preparation
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease

Also Published As

Publication number Publication date
WO2014124978A4 (en) 2014-12-24
CA2898798A1 (en) 2014-08-21
PH12015501762A1 (en) 2015-11-09
BR112015019220A2 (pt) 2017-07-18
WO2014124978A2 (en) 2014-08-21
EP2956134A2 (en) 2015-12-23
US20150374676A1 (en) 2015-12-31
JP2016507546A (ja) 2016-03-10
IL240459A0 (en) 2015-09-24
AU2014217962A1 (en) 2015-09-17
MX2015010339A (es) 2015-11-16
CL2015002241A1 (es) 2016-02-19
WO2014124978A3 (en) 2014-10-30
ZA201505243B (en) 2017-11-29
KR20150119089A (ko) 2015-10-23
CN105101963A (zh) 2015-11-25
SG11201506153TA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
EA201691354A1 (ru) Терапевтические ингибирующие соединения
EA201500836A1 (ru) Ингибиторы хеликазы-примазы для применения в способе лечения болезни альцгеймера
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201690898A1 (ru) Способы лечения таупатии
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
GEP20227369B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
MY195437A (en) Methods of Treatment for Cholestatic and Fibrotic Diseases
EA201690212A8 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
EA201391582A1 (ru) Режимы повышения дозы антител против ip-10
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
BR112019006887A2 (pt) ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias
DK2968470T3 (da) Modificeret müllersk inhiberende substans (mis)-proteiner og anvendelser deraf til behandlingen af sygdomme
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201590111A1 (ru) Моноклональное антитело человека против белка vp1 вируса jc
EA201791471A1 (ru) Способы применения антисмысловых олигонуклеотидов smad7
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
CL2011003002A1 (es) Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
AR108890A1 (es) Inhibidores de la entrada del cmvh